Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: haroldhecubah who wrote (49227)	7/19/2020 3:40:27 PM
From: ciao888	Respond to of 49402

Hi Harold, Yeah. I agree with your assessment. The lack of patience over the past few years have been related to missing timelines rather than getting promised results (with a PGX commercial agreement considered to be long overdue). I've made comparisons to SONA on SH forum as I post as Ciao. Also note this dead stock specific CZO thread that only I have posted in the past 4 years. Subject 19705 I first bought into CZO in mid 2014 when it was in the mid .20's and had EPS of .04 for first 6 months. It was value play for me based on sales of AV/BG. The company has evolved and it looks as those who bought into the BNN hype in 2016 likely left and will not be back if they got burned. Hoping to see last weeks trend continue this week and into the rest of the year.

To: haroldhecubah who wrote (49227)	8/4/2020 12:44:00 PM
From: ciao888	Respond to of 49402

CEAPRO NR EDMONTON, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that positive results demonstrating the anti-inflammatory and immunomodulating properties of avenanthramides have been accepted for publication in the international, peer-reviewed Journal of theInternational Society of Sports Nutrition. The article titled “ Avenanthramide supplementation reduces exercise-induced inflammation in young men and women,” is now available online. The study was co-funded by Pepsi Co and Ceapro Inc. Gilles Gagnon, M.Sc., MBA, President and CEO, commented “We are pleased with the results from the work conducted by the team led by Dr. Li Li Ji and Dr. Zhang at the University of Minnesota and to have these positive results accepted for publication in this internationally renowned Journal. The acceptance of these data for publication bolster both our confidence in our flagship product avenanthramides and our belief in the potential Ceapro has in expanding into a biopharmaceutical company. These studies, while they were conducted using avenanthramides in food, provide a solid foundation for our research team as they move forward and conduct a safety and bioavailability study using proprietary, pure pharmaceutical-grade powder formulation of avenanthramides. The safety and bioavailability study will evaluate avenanthramides as a stand-alone therapy or potentially in combination with carriers recently developed using our PGX technology to address some inflammation-based diseases, which we believe shows great promise.” Would PepsiCo use AV as a food additive and do a commercial deal? Would CZO continue on with a AV pharma grade pill on their own?